Tislelizumab Combing Chemoradiotherapy in Recurrent Cervical Cancer
NCT05863260
·
clinicaltrials.gov ↗
UNKNOWN
Status
60
Enrollment
OTHER
Sponsor class
Conditions
Cervical Cancer
Immune Checkpoint Inhibitor
Chemoradiotherapy
Interventions
DRUG:
Treatment Group
Sponsor
Fudan University